As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

January jobs data is due on Friday. Plus, earnings from AMD, Alphabet, Chipotle, PayPal, Disney, Eli Lilly, Qualcomm, Amazon, ...

Eli Lilly has unveiled a $2.5 billion deal to acquire ... Faeth Therapeutics, Junshi Bio, Jiangsu Hansoh, and BridgeBio at or near the clinical testing stage. Roche gets the first FDA approval ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (the "Company" or " ...